Search Results - "Micantonio, Tamara"

Refine Results
  1. 1

    Dermoscopy in the diagnosis and management of non-melanoma skin cancers by FARGNOLI, Maria Concetta, KOSTAKI, Dimitra, PICCIONI, Antonella, MICANTONIO, Tamara, PERIS, Ketty

    Published in EJD. European journal of dermatology (01-07-2012)
    “…Over the past two decades, dermoscopy has remarkably enhanced the diagnostic accuracy of pigmented skin lesions and, more recently, of non-pigmented skin…”
    Get full text
    Journal Article
  2. 2

    The spectrum of dermatoscopic patterns in blue nevi by Di Cesare, Antonella, MD, Sera, Francesco, BSc, Gulia, Andrea, MD, Coletti, Gino, MD, Micantonio, Tamara, MD, Fargnoli, Maria Concetta, MD, Peris, Ketty, MD

    “…Background Blue nevi are congenital or acquired, dermal dendritic melanocytic proliferations that can simulate melanocytic and nonmelanocytic lesions including…”
    Get full text
    Journal Article
  3. 3

    Dermoscopic patterns of acral melanocytic nevi and melanomas in a white population in central Italy by Altamura, Davide, Altobelli, Emma, Micantonio, Tamara, Piccolo, Domenico, Fargnoli, Maria Concetta, Peris, Ketty

    Published in Archives of dermatology (1960) (01-09-2006)
    “…To investigate the dermoscopic features of acral melanocytic lesions in a white population in central Italy. Retrospective review. University dermatology…”
    Get more information
    Journal Article
  4. 4

    A new dermoscopic algorithm for the differential diagnosis of facial lentigo maligna and pigmented actinic keratosis by Micantonio, Tamara, Neri, Luca, Longo, Caterina, Grassi, Simone, Di Stefani, Alessandro, Antonini, Ambra, Coco, Valeria, Fargnoli, Maria Concetta, Argenziano, Giuseppe, Peris, Ketty

    Published in EJD. European journal of dermatology (01-03-2018)
    “…Background The clinical and dermoscopic diagnosis of facial lentigo maligna (LM) and pigmented actinic keratosis (PAK) remains challenging, particularly at the…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Imiquimod 5% cream in the treatment of Bowen's disease and invasive squamous cell carcinoma by Peris, Ketty, Micantonio, Tamara, Fargnoli, Maria Concetta, Lozzi, Gian Piero, Chimenti, Sergio

    “…Imiquimod has been successfully used for treatment of various epithelial cutaneous neoplasms. Our aim was to evaluate the efficacy and tolerability of…”
    Get full text
    Journal Article
  7. 7

    Dermoscopic features of actinic keratosis by Peris, Ketty, Micantonio, Tamara, Piccolo, Domenico, Concetta, Maria

    “…Summary Actinic keratosis (AK) is a keratinocytic neoplasm that typically develops on sun‐damaged skin of elderly individuals. Only a few reports so far have…”
    Get full text
    Journal Article
  8. 8
  9. 9
  10. 10

    Imiquimod Treatment of Superficial and Nodular Basal Cell Carcinoma: 12-Week Open-Label Trial by Peris, Ketty, Campione, Elena, Micantonio, Tamara, Marulli, Georgiana Clar, Fargnoli, Maria Concetta, Chimenti, Sergio

    Published in Dermatologic surgery (01-03-2005)
    “…BACKGROUNDImiquimod is an immune response modifier shown to be effective in basal cell carcinoma (BCC). OBJECTIVETo evaluate the efficacy, tolerability, and…”
    Get full text
    Journal Article
  11. 11

    Staging and follow-up of cutaneous melanoma patients by Gutiérrez García-Rodrigo, Carlota, Antonini, Ambra, Rocco, Tea, Pellegrini, Cristina, Micantonio, Tamara, Fargnoli, Maria C

    “…Melanoma is responsible for the greatest number of deaths caused by skin malignancies. The purpose of monitoring patients diagnosed with melanoma is to allow…”
    Get more information
    Journal Article
  12. 12

    Imiquimod Treatment of Superficial and Nodular Basal Cell Carcinoma: 12‐Week Open‐Label Trial by Peris, Ketty, Campione, Elena, Micantonio, Tamara, Clare Marulli, Georgiana, Concetta Fargnoli, Maria, Chimenti, Sergio

    Published in Dermatologic surgery (01-03-2005)
    “…Background Imiquimod is an immune response modifier shown to be effective in basal cell carcinoma (BCC). Objective To evaluate the efficacy, tolerability, and…”
    Get full text
    Journal Article
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20